UAE Hemodialysis Vascular Grafts Market Report 2023 to 2030

UAE Hemodialysis Vascular Grafts Market Analysis

$ 3999

UAE Hemodialysis Vascular Grafts Market was valued at $1.05 Bn in 2023 and is predicted to grow at a CAGR of 6.1% from 2023 to 2030, to $1.59 Bn by 2030. The key drivers of this industry include the rising prevalence of end-stage renal disease, the growing geriatric population, and government investment in healthcare. The industry is primarily dominated by W. L. Gore, C. R. Bard, Vascudyne, and LeMaitre among others.

ID: IN10AEMD026 CATEGORY: Medical Devices GEOGRAPHY: UAE AUTHOR: Sarita Yadav

Buy Now

UAE Hemodialysis Vascular Grafts Market Executive Summary

UAE Hemodialysis Vascular Grafts Market was valued at $1.05 Bn in 2023 and is predicted to grow at a CAGR of 6.1% from 2023 to 2030, to $1.59 Bn by 2030.

Hemodialysis vascular grafts are specialized devices crucial for establishing vascular access in patients, particularly those with end-stage renal disease (ESRD) undergoing hemodialysis. These grafts function as conduits, linking an artery to a vein to facilitate blood movement to and from the dialysis machine during treatment. They are designed to provide durable and reliable access, replacing or augmenting natural blood vessels that may not withstand the frequent punctures required in dialysis sessions. Common types include synthetic grafts made from materials like polytetrafluoroethylene (PTFE) or expanded polytetrafluoroethylene (ePTFE), and biological grafts derived from treated animal tissue. Surgical implantation involves connecting the graft in the arm or leg, ensuring proper placement and meticulous care to maintain sufficient blood flow and mitigate complications such as infection or clotting.

Chronic kidney disease (CKD) affects a substantial global population, with an estimated prevalence of 13.4%, translating to about 850 Mn individuals worldwide. Regarding end-stage renal disease (ESRD), global estimates suggest between 4.902 and 7.083 million patients requiring renal replacement therapy. These statistics underscore the significant burden of kidney diseases globally, highlighting the critical need for effective renal care solutions and treatments like hemodialysis and vascular grafts.

The market therefore is driven by significant factors like the rising prevalence of end-stage renal disease, the growing geriatric population, and government investment in healthcare. However, the high cost of treatment, shortage of qualified healthcare professionals, and availability of alternative treatment options restrict the growth and potential of the market.

Prominent players in this field are W. L. Gore who offers the PROPATEN graft with a special heparin surface to fight clotting and the ACUSEAL graft designed for early use after implantation and C. R. Bard provides traditional ePTFE grafts and the innovative Vectra graft made from a different material that may allow for quicker access compared to standard options. Other contributors include Vascudyne, Inc., and LeMaitre among others.

UAE Hemodialysis Vascular Grafts Market Report 2023 to 2030

Market Dynamics

Market Growth Drivers

Rising prevalence of End-Stage Renal Disease (ESRD): UAE has a growing population with a high prevalence of diabetes and hypertension, both significant risk factors for ESRD. This increasing ESRD population will require consistent hemodialysis treatment, driving the demand for vascular grafts to create access points for blood flow.

Growing Geriatric Population: The UAE currently has a young population, with 4.4% to 6.9% aged 65 and above as of 2010 and 2020. By 2050, the elderly aged 60+ may reach 25% of the population, around 40 Mn people, a fivefold increase from 2020. This shift raises CKD risks, driving future demand for hemodialysis vascular grafts.

Government Investment in Healthcare: The UAE government is actively investing in improving healthcare infrastructure and access to advanced medical technologies. This includes support for nephrology services and dialysis facilities, potentially leading to an increase in hemodialysis procedures and vascular graft utilization.

Market Restraints

High Cost of Treatment: Hemodialysis is an expensive treatment, and vascular grafts contribute to the overall cost. Reimbursement policies and patient affordability limit widespread access to these procedures.

Shortage of Qualified Professionals: UAE is experiencing a shortage of nephrologists and vascular surgeons essential for performing hemodialysis access procedures and managing related complications. This limited workforce leads to longer wait times for procedures, potentially hindering the broader adoption of hemodialysis and negatively impacting the market for vascular grafts.

Availability of alternative treatment options: The rise in kidney transplantation rates, supported by advancements in procedures and therapies, offers a compelling alternative to hemodialysis, reducing reliance on vascular grafts and shaping market demand accordingly.

Regulatory Landscape and Reimbursement Scenario

In the UAE, the Ministry of Health and Prevention (MoHAP) regulates medical devices, including hemodialysis vascular grafts, employing a risk-based approach. Lower-risk grafts may undergo simpler registration processes, while higher-risk devices require more comprehensive evaluations, potentially involving clinical data or inspections. The UAE actively participates in global harmonization initiatives like the Global Harmonization Task Force (GHTF), aiming to align regulations with international standards to facilitate expedited market entry for devices already approved in stringent jurisdictions. While special economic free zones exist with distinct regulatory requirements, nationwide distribution mandates MoHAP approval.

Healthcare in the UAE is predominantly funded through government schemes like the Seha program, ensuring coverage for essential medical treatments including hemodialysis for Emirati citizens. However, a significant portion of the population relies on private health insurance, where coverage for hemodialysis procedures and associated materials varies based on individual plans and may include co-payments. Transparency in reimbursement policies and effective negotiation among stakeholders—manufacturers, healthcare providers, and insurers—are critical for ensuring market access and affordability of hemodialysis vascular grafts in the UAE.

Competitive Landscape

Key Players

Here are some of the major key players in the UAE Hemodialysis Vascular Grafts Market

W. L. Gore & Associates, Inc.,
C. R. Bard, Inc.,
Vascudyne, Inc.,
LeMaitre,
Getinge AB,
Vascular Genesis,
InnAVasc Medical, Inc.
CryoLife, Inc.
Merit Medical Systems
Biovic Sdn Bhd.

1. Executive Summary
1.1 Device Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Regulatory Landscape for Medical Device
1.6 Health Insurance Coverage in Country
1.7 Type of Medical Device
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

UAE Hemodialysis Vascular Grafts Market Segmentation

Based on Raw Material

Polytetrafluoroethylene
Polyester
Biological materials
Polyurethane

Based on Indication

Endovascular aneurysm repair
Peripheral vascular repair
Hemodialysis Access

Based on End-User

Hospitals
Clinics
Others (Ambulatory surgical centers)

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.